vs
Side-by-side financial comparison of Workday, Inc. (WDAY) and Zoetis (ZTS). Click either name above to swap in a different company.
Workday, Inc. is the larger business by last-quarter revenue ($2.4B vs $2.4B, roughly 1.0× Zoetis). Zoetis runs the higher net margin — 25.3% vs 10.4%, a 14.9% gap on every dollar of revenue. On growth, Workday, Inc. posted the faster year-over-year revenue change (12.6% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $550.0M). Over the past eight quarters, Workday, Inc.'s revenue compounded faster (12.5% CAGR vs 4.4%).
Workday, Inc. is a leading global enterprise cloud software provider that develops and distributes human capital management, financial management, and enterprise resource planning solutions. It caters primarily to mid-sized and large organizations across sectors including education, healthcare, finance, and technology, with operations spanning North America, Europe, and Asia Pacific.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
WDAY vs ZTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.4B | $2.4B |
| Net Profit | $252.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 10.6% | 31.9% |
| Net Margin | 10.4% | 25.3% |
| Revenue YoY | 12.6% | 3.0% |
| Net Profit YoY | 30.6% | 3.8% |
| EPS (diluted) | $0.94 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.4B | $2.4B | ||
| Q3 25 | $2.3B | $2.4B | ||
| Q2 25 | $2.2B | $2.5B | ||
| Q1 25 | $2.2B | $2.2B | ||
| Q4 24 | $2.2B | $2.3B | ||
| Q3 24 | $2.1B | $2.4B | ||
| Q2 24 | $2.0B | $2.4B | ||
| Q1 24 | $1.9B | $2.2B |
| Q4 25 | $252.0M | $603.0M | ||
| Q3 25 | $228.0M | $721.0M | ||
| Q2 25 | $68.0M | $718.0M | ||
| Q1 25 | $94.0M | $631.0M | ||
| Q4 24 | $193.0M | $581.0M | ||
| Q3 24 | $132.0M | $682.0M | ||
| Q2 24 | $107.0M | $624.0M | ||
| Q1 24 | $1.2B | $599.0M |
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% | ||
| Q1 24 | — | 70.6% |
| Q4 25 | 10.6% | 31.9% | ||
| Q3 25 | 10.6% | 37.0% | ||
| Q2 25 | 1.7% | 36.7% | ||
| Q1 25 | 3.4% | 36.5% | ||
| Q4 24 | 7.6% | 31.6% | ||
| Q3 24 | 5.3% | 36.6% | ||
| Q2 24 | 3.2% | 33.0% | ||
| Q1 24 | 4.1% | 34.1% |
| Q4 25 | 10.4% | 25.3% | ||
| Q3 25 | 9.7% | 30.0% | ||
| Q2 25 | 3.0% | 29.2% | ||
| Q1 25 | 4.3% | 28.4% | ||
| Q4 24 | 8.9% | 25.1% | ||
| Q3 24 | 6.3% | 28.6% | ||
| Q2 24 | 5.4% | 26.4% | ||
| Q1 24 | 61.8% | 27.4% |
| Q4 25 | $0.94 | $1.37 | ||
| Q3 25 | $0.84 | $1.63 | ||
| Q2 25 | $0.25 | $1.61 | ||
| Q1 25 | $0.34 | $1.41 | ||
| Q4 24 | $0.72 | $1.29 | ||
| Q3 24 | $0.49 | $1.50 | ||
| Q2 24 | $0.40 | $1.37 | ||
| Q1 24 | $4.48 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.8B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.9B | $3.3B |
| Total Assets | $17.8B | $15.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.8B | — | ||
| Q3 25 | $8.2B | $2.1B | ||
| Q2 25 | $8.0B | $1.4B | ||
| Q1 25 | $8.0B | $1.7B | ||
| Q4 24 | $7.2B | $2.0B | ||
| Q3 24 | $7.4B | $1.7B | ||
| Q2 24 | $7.2B | $1.6B | ||
| Q1 24 | $7.8B | $2.0B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $3.0B | — | ||
| Q1 24 | $3.0B | — |
| Q4 25 | $8.9B | $3.3B | ||
| Q3 25 | $9.2B | $5.4B | ||
| Q2 25 | $8.9B | $5.0B | ||
| Q1 25 | $9.0B | $4.7B | ||
| Q4 24 | $8.6B | $4.8B | ||
| Q3 24 | $8.3B | $5.2B | ||
| Q2 24 | $8.2B | $5.0B | ||
| Q1 24 | $8.1B | $5.1B |
| Q4 25 | $17.8B | $15.5B | ||
| Q3 25 | $18.0B | $15.2B | ||
| Q2 25 | $17.2B | $14.5B | ||
| Q1 25 | $18.0B | $14.1B | ||
| Q4 24 | $16.4B | $14.2B | ||
| Q3 24 | $16.2B | $14.4B | ||
| Q2 24 | $15.9B | $14.2B | ||
| Q1 24 | $16.5B | $14.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 0.37× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $588.0M | $893.0M |
| Free Cash FlowOCF − Capex | $550.0M | $732.0M |
| FCF MarginFCF / Revenue | 22.6% | 30.7% |
| Capex IntensityCapex / Revenue | 1.6% | 6.7% |
| Cash ConversionOCF / Net Profit | 2.33× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $2.6B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $588.0M | $893.0M | ||
| Q3 25 | $616.0M | $938.0M | ||
| Q2 25 | $457.0M | $486.0M | ||
| Q1 25 | $1.1B | $587.0M | ||
| Q4 24 | $406.0M | $905.0M | ||
| Q3 24 | $571.0M | $951.0M | ||
| Q2 24 | $372.0M | $502.0M | ||
| Q1 24 | $995.6M | $595.0M |
| Q4 25 | $550.0M | $732.0M | ||
| Q3 25 | $588.0M | $805.0M | ||
| Q2 25 | $421.0M | $308.0M | ||
| Q1 25 | $1.0B | $438.0M | ||
| Q4 24 | $359.0M | $689.0M | ||
| Q3 24 | $516.0M | $784.0M | ||
| Q2 24 | $291.0M | $370.0M | ||
| Q1 24 | $947.6M | $455.0M |
| Q4 25 | 22.6% | 30.7% | ||
| Q3 25 | 25.0% | 33.5% | ||
| Q2 25 | 18.8% | 12.5% | ||
| Q1 25 | 46.4% | 19.7% | ||
| Q4 24 | 16.6% | 29.7% | ||
| Q3 24 | 24.7% | 32.8% | ||
| Q2 24 | 14.6% | 15.7% | ||
| Q1 24 | 49.3% | 20.8% |
| Q4 25 | 1.6% | 6.7% | ||
| Q3 25 | 1.2% | 5.5% | ||
| Q2 25 | 1.6% | 7.2% | ||
| Q1 25 | 3.9% | 6.7% | ||
| Q4 24 | 2.2% | 9.3% | ||
| Q3 24 | 2.6% | 7.0% | ||
| Q2 24 | 4.1% | 5.6% | ||
| Q1 24 | 2.5% | 6.4% |
| Q4 25 | 2.33× | 1.48× | ||
| Q3 25 | 2.70× | 1.30× | ||
| Q2 25 | 6.72× | 0.68× | ||
| Q1 25 | 11.83× | 0.93× | ||
| Q4 24 | 2.10× | 1.56× | ||
| Q3 24 | 4.33× | 1.39× | ||
| Q2 24 | 3.48× | 0.80× | ||
| Q1 24 | 0.84× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
WDAY
| Subscription Services | $2.2B | 92% |
| Professional Services | $188.0M | 8% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
